Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
04/06/2026 23:28
BRIEF-Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline June 4 (Reuters) - Gilead Sciences, Inc GILD.O:
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Source text: ID:nBw2pGdFya
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline